ISDA

Entry Detail

PDB ID:

7CJF

Keywords:

VIRAL PROTEIN

Title:

Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab

Biological Source:

Source Organism:

Homo sapiens, Severe acute respiratory syndrome coronavirus 2

Host Organism:

Homo sapiens

PDB Version:

Deposition Date:

2020-07-10

Release Date:

2020-11-11

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.11 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

C 2 2 21

Download Validation Report

Macromolecular Entities

Polymer Type:polypeptide(L)
Description:antibody heavy chain
Chain IDs:A
Chain Length:228
Number of Molecules:1
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Description:antibody light chain
Chain IDs:B
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens

Protein Blast

Polymer Type:polypeptide(L)
Description:Spike protein S1
Chain IDs:C
Chain Length:194
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF09408

Ligand Molecules

NAG

Primary Citation

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.

Guo, Y, Huang, L, Zhang, G, Yao, Y, Zhou, H, Shen, S, Shen, B, Li, B, Li, X, Zhang, Q, Chen, M, Chen, D, Wu, J, Fu, D, Zeng, X, Feng, M, Pi, C, Wang, Y, Zhou, X, Lu, M, Li, Y, Fang, Y, Lu, Y.Y, Hu, X, Wang, S, Zhang, W, Gao, G, Adrian, F, Wang, Q, Yu, F, Peng, Y, Gabibov, A.G, Min, J, Wang, Y, Huang, H, Stepanov, A, Zhang, W, Cai, Y, Liu, J, Yuan, Z, Zhang, C, Lou, Z, Deng, F, Zhang, H, Shan, C, Schweizer, L, Sun, K, Rao, Z.Show

Nat Commun 12 2623 2623 (2021)

PMID: 33976198 DOI: 10.1038/s41467-021-22926-2

Abstact

COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight COVID-19, especially for the most vulnerable populations. In this work, potent antibodies binding to SARS-CoV-2 Spike protein were identified from COVID-19 convalescent patients. Among them, P4A1 interacts directly with and covers majority of the Receptor Binding Motif of the Spike Receptor-Binding Domain, shown by high-resolution complex structure analysis. We further demonstrate the binding and neutralizing activities of P4A1 against wild type and mutant Spike proteins or pseudoviruses. P4A1 was subsequently engineered to reduce the potential risk for Antibody-Dependent Enhancement of infection and to extend its half-life. The engineered antibody exhibits an optimized pharmacokinetic and safety profile, and it results in complete viral clearance in a rhesus monkey model of COVID-19 following a single injection. These data suggest its potential against SARS-CoV-2 related diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures